About ASCIL Biopharm 




Innovative Drug Delivery System Company

Specialist  in Biotech & Med Tech projects

Advanced formulations, Drug product CMC, proprietary biocompatible technologies, compositions, processes and medical devices 

Healthcare and Life-sciences






The Company 


ASCIL BIOPHARM is a consolidated International Biomedical Company based in Barcelona, launched in 2012. 

We are specialized in Applied R+D+I of innovative Drug Delivery Systems (DDS): Advanced nanosystems, Galenic, Drug product CMC from proprietary science and technology to new patentable medicines.

Our fields of activity are the Pharma, Biotech, Aesthetic and Veterinary Care Innovations.



Our Mission 




ASCIL BIO
PHARM aims to create and improve Pharmaceuticals and Biotech Treatments thanks to Innovative DDS platforms and our Unique Expertise.

We offer pragmatic and competitive Product-Device combination.











The Team 


Our added value : Integrated “Bio-engineer” pharmaceutical innovation platform to deliver Tailor-made patented  


Our Team of Controlled release specialists gathers more than 200 years of experience in the R&D of therapeutic products up to market  for Public organizations and Private Pharma companies.

Proven back record  of success of inventions
Unique Experience in the Following R+D+I Scientific Areas of Polypeptides delivery and Controlled release injectable DDS :
  • Preformulation, advanced galenics, formulation, physicochemical, nanosciences, peptide self assembly & pharmaceutical analysis - innovation and development focused on Drug Product CMC
  • Advanced bio-pharma CMC technologies, engineering and processes, from lab bench to industrial validation
  • Bioanalysis and biopharmacy (preclinical management and clinical follow-up)
  • Medical technology: devices for administration, design of specific containers closure systems (own workshop)

Fully Internal equipped laboratories to carry out activity in confidential environment 




Our Business

 


ASCIL Biopharm cooperates in a Project awarded with a “RETOS-Colaboración” grant

Ascil Biopharm takes part in a public-private consortium led by the biotech Iproteos and comprised by the Institute for Biomedical Research (IRB Barcelona), the Centre for Genomic Regulation (CRG) and the University of the Basque Country (UPV/EHU) to advance the preclinical development of a new neuroprotective drug (IPR19) for the treatment of the cognitive impairment associated with schizophrenia and other mental disorders. The Project, called "SPARK", has received a 500,000 € grant from the Ministry of Economy and Finance, through the 2014 "RETOS-Colaboración" subprogram as part of the National Program for Research Aimed at the Challenges of Society (See link below)

http://www.boe.es/boe/dias/2015/01/02/pdfs/BOE-A-2015-33.pdf



Our premises 







ASCIL Biopharm operates within the Barcelona Tech Science Park of the Polytechnical University of Catalonia (UPC) where we have 500 m² of operational dedicated R+D+I facilities in Viladecans (Barcelona) including 5 laboratories (we are just at 2 min from Barcelona international airport)
 











 

Join the Team 


To carry out our pipeline, we are actively consolidating our Scientific & Technical highly skilled team with various positions (Scientists in analysis formulation or medical devices and one position in Business innovation).

Please apply to rrhh@ascil-biopharm.com